These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 8239624)

  • 41. In vitro antibacterial activities of PD 138312 and PD 140248, new fluoronaphthyridines with outstanding gram-positive potency.
    Huband MD; Cohen MA; Meservey MA; Roland GE; Yoder SL; Dazer ME; Domagala JM
    Antimicrob Agents Chemother; 1993 Dec; 37(12):2563-70. PubMed ID: 8109918
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacodynamic properties of BAY 12-8039 on gram-positive and gram-negative organisms as demonstrated by studies of time-kill kinetics and postantibiotic effect.
    Boswell FJ; Andrews JM; Wise R
    Antimicrob Agents Chemother; 1997 Jun; 41(6):1377-9. PubMed ID: 9174203
    [TBL] [Abstract][Full Text] [Related]  

  • 43. E-4695, a new C-7 azetidinyl fluoronaphthyridine with enhanced activity against gram-positive and anaerobic pathogens.
    Guinea J; Gargallo-Viola D; Robert M; Tudela E; Xicota MA; Garcia J; Esteve M; Coll R; Pares M; Roser R
    Antimicrob Agents Chemother; 1995 Feb; 39(2):413-21. PubMed ID: 7726507
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparative activity of garenoxacin and other agents by susceptibility and time-kill testing against Staphylococcus aureus, Streptococcus pyogenes and respiratory pathogens.
    Noviello S; Ianniello F; Leone S; Esposito S
    J Antimicrob Chemother; 2003 Nov; 52(5):869-72. PubMed ID: 14519672
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Activity of temafloxacin against respiratory pathogens.
    Swanson RN; Hardy DJ; Chu DT; Shipkowitz NL; Clement JJ
    Antimicrob Agents Chemother; 1991 Mar; 35(3):423-9. PubMed ID: 2039192
    [TBL] [Abstract][Full Text] [Related]  

  • 46. In vitro susceptibility of 4903 bacterial isolates to gemifloxacin--an advanced fluoroquinolone.
    Blondeau JM; Hansen G; Metzler KL; Borsos S; Irvine LB; Blanco L
    Int J Antimicrob Agents; 2003 Aug; 22(2):147-54. PubMed ID: 12927955
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Susceptibility of European respiratory tract isolates to trovafloxacin, ciprofloxacin, clarithromycin, azithromycin and ampicillin.
    Pontani D; Washton H; Bouchillon S; Johnson J
    Eur J Clin Microbiol Infect Dis; 1998 Jun; 17(6):413-9. PubMed ID: 9758284
    [TBL] [Abstract][Full Text] [Related]  

  • 48. In-vitro activity of WIN 57273 compared to the activity of other fluoroquinolones and two beta-lactam antibiotics.
    Chin NX; Neu HC
    J Antimicrob Chemother; 1991 Jun; 27(6):781-91. PubMed ID: 1657856
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Antibacterial activities of grepafloxacin, ciprofloxacin, ofloxacin and fleroxacin.
    Barry AL; Fuchs PC
    J Chemother; 1997 Feb; 9(1):9-16. PubMed ID: 9106012
    [TBL] [Abstract][Full Text] [Related]  

  • 50. In vitro activity of DU-6859a, a new fluorocyclopropyl quinolone.
    Marshall SA; Jones RN
    Antimicrob Agents Chemother; 1993 Dec; 37(12):2747-53. PubMed ID: 8109948
    [TBL] [Abstract][Full Text] [Related]  

  • 51. In-vitro activity of trovafloxacin, a new fluoroquinolone, against recent clinical isolates.
    Felmingham D; Robbins MJ; Ingley K; Mathias I; Bhogal H; Leakey A; Ridgway GL; Grüneberg RN
    J Antimicrob Chemother; 1997 Jun; 39 Suppl B():43-9. PubMed ID: 9222069
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Antimicrobial activity evaluations of two new quinolones, PD127391 (CI-960 and AM-1091) and PD131628.
    Barrett MS; Jones RN; Erwin ME; Johnson DM; Briggs BM
    Diagn Microbiol Infect Dis; 1991; 14(5):389-401. PubMed ID: 1665774
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1995). I. Susceptibility distribution].
    Kumamoto Y; Tsukamoto T; Hirose T; Yokoo A; Hikichi Y; Shigeta S; Takanashi T; Shiraiwa Y; Ogiwara M; Yoshida H; Imafuku Y; Murai M; Watanabe K; Uchida H; Kobayashi Y; Matsuda S; Fujime M; Fujita K; Igari J; Oguri T; Kosakai N; Yamaguchi K; Matsumoto T; Kashitani F; Tanaka M
    Jpn J Antibiot; 1997 Mar; 50(3):219-50. PubMed ID: 9575353
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Moxifloxacin activity against clinical isolates compared with the activity of ciprofloxacin.
    Aktaş Z; Gönüllü N; Salcioğlu M; Bal C; Anğ O
    Int J Antimicrob Agents; 2002 Sep; 20(3):196-200. PubMed ID: 12385698
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Antibacterial activity of tosufloxacin against fresh clinical isolates].
    Yamashiro Y; Shimakura M; Minami S; Fukuoka Y; Yasuda T; Watanabe Y; Narita H; Akama M
    Jpn J Antibiot; 1994 Mar; 47(3):245-54. PubMed ID: 8182895
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from urinary tract infections (1992). I. Susceptibility distribution].
    Kumamoto Y; Hirose T; Tanaka N; Hikichi Y; Shigeta S; Shiraiwa Y; Kameoka H; Yoshida H; Ogata M; Tazaki H
    Jpn J Antibiot; 1995 Nov; 48(11):1627-57. PubMed ID: 8558754
    [TBL] [Abstract][Full Text] [Related]  

  • 57. In vitro activity of fleroxacin (Ro23-6240), a new fluorinated 4-quinolone against isolates from cancer patients.
    Rolston K; Ho DH; LeBlanc B; Bodey GP
    Chemotherapy; 1988; 34(6):448-54. PubMed ID: 3149568
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1996). I. Susceptibility distribution].
    Kumamoto Y; Tsukamoto T; Hirose T; Yokoo A; Shigeta S; Takahashi T; Shiraiwa Y; Ogiwara M; Yoshida H; Imafuku Y; Murai M; Watanabe K; Uchida H; Kobayashi Y; Matsuda S; Fujime M; Fujita K; Igari J; Oguri T; Yamaguchi K; Matsumoto T; Kashitani F; Kaku M; Ooe H; Mochida C
    Jpn J Antibiot; 1998 Feb; 51(2):69-111. PubMed ID: 9575437
    [TBL] [Abstract][Full Text] [Related]  

  • 59. In vitro antibacterial spectrum of a new broad-spectrum 8-methoxy fluoroquinolone, gatifloxacin.
    Fung-Tomc J; Minassian B; Kolek B; Washo T; Huczko E; Bonner D
    J Antimicrob Chemother; 2000 Apr; 45(4):437-46. PubMed ID: 10747819
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [In vitro activity of trovafloxacin in 238 respiratory pathogens].
    Alarcón T; Domingo D; Prieto N; Sánchez S; López-Brea M
    Rev Esp Quimioter; 1998 Mar; 11(1):47-51. PubMed ID: 9795289
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.